Navigation Links
No difference in death rates among patients exposed to common rheumatoid arthritis drugs
Date:8/7/2012

New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Swedenthe first to compare mortality rates among patients treated with individual TNF inhibitorsis now available in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).

RA is a chronic, autoimmune disease characterized by inflammation in the joints that causes pain, tenderness and swelling. The World Health Organization estimates that RA affects up to one percent of individuals worldwide, with more than one million Americans diagnosed with the disease according to the ACR. Rheumatologists recommend early intervention with biologic disease modifying anti-rheumatic drugs (DMARDs) such as TNF inhibitors to slow disease progression, improve function, and prevent disability.

In Sweden nearly 15% of RA patients are prescribed TNF inhibitors. The present study examined the mortality rates in RA patients exposed to adalimumab, etanercept, or infliximab. "Understanding risk versus benefits of treatment with the most commonly prescribed biologics is important for physicians and patients in managing RA," said lead author Dr. Julia Fridman Simard with the Clinical Epidemiology Unit at Karolinska Institute in Stockholm, Sweden.

Researchers linked data from the Swedish Biologics Register (ARTIS), a comprehensive database of patients initiating first-ever biologic therapy for rheumatic diseases, and information from national Swedish registers that included data such as all-cause mortality, demographics, and RA characteristics. Between 2003 and 2008, 1,609 patients with RA initiated treatment with adalimumab, 2,686 with etanercept, and 2,027 with infliximab as their first ever biologic DMARD.

There were more than 19,000 person-years of follow-up during the five-year study period during which time 211 patients died (3.3%). "While we found no statistically significant difference in mortality rates across the three biologic therapies, further studies are needed to determine if this is true across certain subsets of patients with RA," concludes Dr. Simard.


'/>"/>
Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Study finds significant skull differences between closely linked groups
2. Mayo Clinic study links healthy muscle mass to healthy bones, finds differences by gender
3. Pre-season fitness makes no difference to risk of injury
4. Love Knows No Gender Difference
5. Racial differences in diabetes diagnostic thresholds
6. Higher-spending hospitals have fewer deaths for emergency patients
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Cancer Diagnosis May Raise Odds for Suicide, Heart Attack Death
9. Death From Accidental Injuries Among Kids Drops 30%: CDC
10. Opioids associated with highest risk of death
11. Study reveals major funding shortfall and high death rates for emergency laparotomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Los Angeles, CA (PRWEB) , ... January 18, 2017 , ... ... serious hazards while driving during a rain storm by slowing down and increasing the ... published on Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Sales Focus Inc. ... clients into the US market. , Over the past 20 years SFI has been ... weeks SFI has launched six new clients into the US market. The new ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... of the American Osteopathic College of Proctology) announced today the opening of ... Southern California ( http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles (Beverly Hills), ...
(Date:1/18/2017)... ... January 18, 2017 , ... From a health perspective, 2017 ... daily linking gut health to chronic disease, mental health and general physical well-being. The ... an important resolution to consider. , For one Charlottesville restaurant, good gut health is ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... among specialty pharmacists and pharmacy professionals, has teamed up with Ochsner Health ... program, announced Brian Haug, president of Pharmacy Healthcare Communications, LLC, publishers of ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Jan 18, 2017 Research and Markets has announced ... by End User - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... is expected to reach $5,491 million by 2022, growing at a CAGR ... America was the leading regional market in global vital signs ...
(Date:1/18/2017)... , Jan. 18, 2017  Adaptive Sound Technologies, Inc. (ASTI), ... new partnership with Hyatt Place Nashville/Downtown to deliver the ... LectroFan sleep therapy machines in over two hundred of ... most important parts of having a great stay is ... of Hyatt Place Nashville/Downtown. "We,re pleased to be able ...
(Date:1/18/2017)... N.J. , Jan. 18, 2017   Regenicin, ... a biotechnology company specializing in the development and commercialization ... damaged tissues and organs, recently reported the Company,s operating ... for 2017. As the Company described in ... been a year of substantial accomplishments. The Company,s contract ...
Breaking Medicine Technology: